Trump's recent announcement of imposing approximately 25% tariffs on pharmaceutical imports has sent ripples through the global healthcare sector, particularly affecting India's robust pharmaceutical export industry. It could significantly reshape the US-India pharmaceutical trade relationship. Industry experts have expressed serious concerns about the implications of these tariffs.